{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:29:53Z","timestamp":1790270993331,"version":"4.1.0"},"reference-count":108,"publisher":"Informa UK Limited","issue":"3","funder":[{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GSK\/Stiefel"},{"DOI":"10.13039\/501100022606","name":"Almirall","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100023331","name":"Leo Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Boehringer Ingelheim"},{"DOI":"10.13039\/100016259","name":"Mylan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011284","name":"Valeant","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Samsung"},{"name":"Janssen"},{"name":"Lilly"},{"name":"Menlo"},{"name":"Merck"},{"name":"Novartis"},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sanof"},{"name":"Novan"},{"name":"Qurient"},{"name":"National Biological Corporation"},{"name":"Caremark"},{"name":"Advance Medical"},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Suncare Research"},{"name":"Informa"},{"name":"UpToDate"},{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.2217\/imt-2020-0195","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T08:02:21Z","timestamp":1605686541000},"page":"201-216","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["A Review of Secukinumab in Psoriasis Treatment"],"prefix":"10.1080","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4189-6996","authenticated-orcid":false,"given":"Scott H","family":"Berg","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5577-8838","authenticated-orcid":false,"given":"Esther A","family":"Balogh","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6325-7581","authenticated-orcid":false,"given":"Rima I","family":"Ghamrawi","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA"},{"name":"Department of Dermatology, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13854"},{"issue":"2","key":"e_1_3_3_4_1","first-page":"ii14","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman DD","year":"2005","unstructured":"Gladman DD , AntoniC , MeaseP , CleggDO , NashP. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis.64(Suppl. 2), ii14\u2013ii17 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2009.00024"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.065"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.058"},{"key":"e_1_3_3_8_1","unstructured":"Novartis Pharmaceuticals Corporation\n. Costentyx (secukinumab) [package insert]. U.S. Food and Drug Administration (2020). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125504s031lbl.pdf"},{"key":"e_1_3_3_9_1","unstructured":"Novartis Europharm Limited\n. Costentyx (secukinumab) [summary of product characteristics]. European Medicines Agency (2020). www.ema.europa.eu\/documents\/product-information\/cosentyx-epar-product-information_en.pdf"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"issue":"8","key":"e_1_3_3_11_1","doi-asserted-by":"crossref","first-page":"a015354","DOI":"10.1101\/cshperspect.a015354","article-title":"Psoriasis","volume":"4","author":"Di Meglio P","year":"2014","unstructured":"Di Meglio P , VillanovaF , NestleFO. Psoriasis. Cold Spring Harb. Perspect. Med.4(8), a015354 (2014).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.013"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2586"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.021"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1155\/MI.2005.273"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-007-0329-1"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03704.x"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1229-1"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.029"},{"key":"e_1_3_3_20_1","unstructured":"Novartis Pharmaceuticals Corporation\n. Advisory committee briefing materials: secukinumab (AIN457). (2014). https:\/\/wayback.archive-it.org\/7993\/20170114003828\/http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/DermatologicandOphthalmicDrugsAdvisoryCommittee\/UCM419023.pdf"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.865009"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.058"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051731"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1067\/S0190-9622(03)00910-1"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/839425"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001107"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12110"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12070"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.04.011"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14878"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13814"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.05.013"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.04.045"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13348"},{"issue":"5","key":"e_1_3_3_36_1","first-page":"AB270","article-title":"Secukinumab administration by prefilled syringe maintains efficacy in moderate to severe plaque psoriasis over 100weeks: results of the FEATURE trial","volume":"74","author":"Blauvelt A","year":"2016","unstructured":"Blauvelt A , GottliebA , TyringSet al. Secukinumab administration by prefilled syringe maintains efficacy in moderate to severe plaque psoriasis over 100weeks: results of the FEATURE trial. J. Am. Acad. Dermatol.74(5), AB270 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12751"},{"issue":"5","key":"e_1_3_3_38_1","first-page":"AB270","article-title":"Secukinumab administration by autoinjector maintains efficacy in plaque psoriasis over 2years: results of the JUNCTURE study","volume":"74","author":"Lacour JP","year":"2016","unstructured":"Lacour JP , TedremetsL , KreutzerKet al. Secukinumab administration by autoinjector maintains efficacy in plaque psoriasis over 2years: results of the JUNCTURE study. J. Am. Acad. Dermatol.74(5), AB270 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-018-0265-y"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16558"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13478"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12359"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18143"},{"key":"e_1_3_3_46_1","unstructured":"ClinicalTrials.gov. NCT02748863. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02748863"},{"key":"e_1_3_3_47_1","unstructured":"ClinicalTrials.gov. NCT03589885. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03589885"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15706"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15656"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.008"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14391"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.025"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15707"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13911"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.033"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1329502"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18331"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17351"},{"key":"e_1_3_3_59_1","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study","author":"Reich K","year":"2020","unstructured":"Reich K , SullivanJ , ArenbergerPet al. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br. J. Dermatol. (2020) (Epub ahead of print).","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16705"},{"key":"e_1_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13056"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15387"},{"issue":"3","key":"e_1_3_3_63_1","first-page":"3156","article-title":"Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"8","author":"Xiong HZ","year":"2015","unstructured":"Xiong HZ , GuJY , HeZGet al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. Int. J. Clin. Exp. Med.8(3), 3156\u20133172 (2015).","journal-title":"Int. J. Clin. Exp. Med."},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028015626545"},{"key":"e_1_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.1000"},{"key":"e_1_3_3_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16400"},{"key":"e_1_3_3_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16632"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2016.1255306"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.043"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1708854"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16180"},{"key":"e_1_3_3_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14819"},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16202"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1708897"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1779217"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0328-z"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13306"},{"key":"e_1_3_3_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.01.066"},{"key":"e_1_3_3_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202646"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11097"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex301"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1551-x"},{"key":"e_1_3_3_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-0163-5"},{"issue":"6","key":"e_1_3_3_88_1","first-page":"890","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, Phase III FUTURE 5 study","volume":"77","author":"Mease P","year":"2018","unstructured":"Mease P , VanDer Heijde D , LandeweRet al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, Phase III FUTURE 5 study. Ann. Rheum. Dis.77(6), 890\u2013897 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez420"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30564-X"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23111"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.160275"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1773-y"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23537"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1610-3"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1653-5"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000723"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1957-0"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014042"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.024"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-019-1882-2"},{"key":"e_1_3_3_102_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668"},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15637"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1221923"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.0718"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18981"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15920"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220868"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2020-0195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T18:35:43Z","timestamp":1715970943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2020-0195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.2217\/imt-2020-0195"],"URL":"https:\/\/doi.org\/10.2217\/imt-2020-0195","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,18]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}